• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    11/14/24 7:00:28 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DYN alert in real time by email
    SC 13G/A 1 d912866dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Dyne Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001

    (Title of Class of Securities)

    26818M108

    (CUSIP Number)

    SEPTEMBER 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 76029N106    13G    Page 2 of 9 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     ForDyne B.V.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     5,795,364

       7.  

     SOLE DISPOSITIVE POWER

     0

     

       8.  

     SHARED DISPOSITIVE POWER

     

     5,795,364

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,795,364

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.8% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    1

    This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


    CUSIP No. 76029N106    13G    Page 3 of 9 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Forbion Capital Fund IV Coöperatief U.A.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     4,525,498

       7.  

     SOLE DISPOSITIVE POWER

     0

     

       8.  

     SHARED DISPOSITIVE POWER

     

     4,525,498

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,525,498

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.7% (2)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    2

    This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


    CUSIP No. 76029N106    13G    Page 4 of 9 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Forbion IV Management B.V.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     4,525,498

       7.  

     SOLE DISPOSITIVE POWER

     0

     

       8.  

     SHARED DISPOSITIVE POWER

     

     4,525,498

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,525,498

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.7% (3)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    3

    This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


    CUSIP No. 76029N106    13G    Page 5 of 9 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Forbion Capital Fund II Coöperatief U.A.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     1,428,571

       7.  

     SOLE DISPOSITIVE POWER

     0

     

       8.  

     SHARED DISPOSITIVE POWER

     

     1,428,571

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,428,571

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.4% (4)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    4

    This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


    CUSIP No. 76029N106    13G    Page 6 of 9 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Forbion II Management B.V.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     1,428,571

       7.  

     SOLE DISPOSITIVE POWER

     0

     

       8.  

     SHARED DISPOSITIVE POWER

     

     1,428,571

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,428,571

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.4% (5)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    5

    This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


    CUSIP No. 76029N106    13G    Page 7 of 9 Pages

     

    Item 1(a).

    Name of Issuer:

    Dyne Therapeutics, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    1560 Trapelo Road, Waltham, MA 02451

     

    Item 2(a).

    Name of Person Filing:

    This Statement is being filed by ForDyne B.V. (“ForDyne”), Forbion Capital Fund IV Coöperatief U.A. (“Forbion IV COOP”), Forbion IV Management B.V. (“Forbion IV”), the director of Forbion IV COOP, Forbion Growth Opportunities Fund II Coöperatief U.A. (“Forbion II COOP”) and Forbion Growth II Management B.V. (“Forbion II”), the director of Forbion II COOP. ForDyne is a joint investment vehicle wholly owned by Forbion IV COOP and Forbion II COOP, but does not exercise voting or dispositive power over the shares held on behalf of Forbion IV COOP and Forbion II COOP. The foregoing entities are sometimes referred to collectively herein as the “Reporting Persons”.

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands.

     

    Item 2(c).

    Citizenship:

    ForDyne B.V. – The Netherlands

    Forbion IV COOP – The Netherlands

    Forbion IV – The Netherlands

    Forbion II COOP – The Netherlands

    Forbion II – The Netherlands

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.0001 per share

     

    Item

    2(e). CUSIP Number: 26818M108

     

    Item 3.

     

    Item 4.

    Ownership.

     

    (a)-(b)    Amount beneficially owned, Percent of class: ForDyne directly holds 5,795,364 shares of Common Stock, representing approximately 5.8% of the outstanding Common Stock. ForDyne is a joint investment vehicle wholly owned by Forbion IV COOP and Forbion II COOP, but does not exercise voting or dispositive power over the shares held on behalf of Forbion IV COOP and Forbion II COOP. Forbion IV COOP directly holds 158,705 shares of Common


    CUSIP No. 76029N106    13G    Page 8 of 9 Pages

     

      

    Stock, and may be deemed to beneficially own 4,366,793 shares of Common Stock held directly by ForDyne, representing approximately 4.7% of the outstanding Common Stock. Forbion II COOP may be deemed to beneficially own 1,428,571 shares are held directly by ForDyne, representing approximately 1.4% of the outstanding Common Stock. Forbion IV, the director of Forbion IV COOP, may be deemed to have voting and investment power over the shares beneficially owned by Forbion IV COOP. Forbion II, the director of Forbion II COOP, may be deemed to have voting and investment power over the shares beneficially owned by Forbion II COOP.

     

      (c)

    Number of shares as to which such person has:

     

    Reporting Person

       Sole Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
     

    ForDyne

         0        5,795,364        0        5,795,364  

    Forbion IV COOP

         0        4,525,498        0        4,525,498  

    Forbion IV

         0        4,525,498        0        4,525,498  

    Forbion II COOP

         0        1,428,571        0        1,428,571  

    Forbion II

         0        1,428,571        0        1,428,571  

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    The Reporting Persons are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Reporting Persons disclaim membership in a group and this report shall not be deemed an admission by any of the Reporting Persons that they are or may be members of a “group” for purposes of Rule 13d-5 or for any other purpose.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item

    10. Certification.

    Not applicable .


    CUSIP No. 76029N106    13G    Page 9 of 9 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

     

    FORDYNE B.V.
    By: Forbion International Management B.V., its director
    By:  

    /s/ V. van Houten /s/ H.A. Slootweg

      Name: V. van Houten and H.A. Slootweg
      Title: Directors
    FORBION CAPITAL FUND IV COÖPERATIEF U.A.
    By:   Forbion IV Management B.V., its director
    By:   FCPM III Services B.V., its director
    By:  

    /s/ V. van Houten /s/ H.A. Slootweg

      Name: V. van Houten and H.A. Slootweg
      Title: Directors
    FORBION IV MANAGEMENT B.V.
    By:   FCPM III Services B.V., its director
    By:  

    /s/ V. van Houten /s/ H.A. Slootweg

      Name: V. van Houten and H.A. Slootweg
      Title: Directors
    FORBION CAPITAL FUND II COÖPERATIEF U.A.
    By:   Forbion II Management B.V., its director
    By:   FCPM III Services B.V., its director
    By:  

    /s/ V. van Houten /s/ H.A. Slootweg

      Name: V. van Houten and H.A. Slootweg
      Title: Directors
    FORBION II MANAGEMENT B.V.
    By:   FCPM III Services B.V., its director
    By:  

    /s/ V. van Houten /s/ H.A. Slootweg

      Name: V. van Houten and H.A. Slootweg
      Title: Directors

     

    Get the next $DYN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYN

    DatePrice TargetRatingAnalyst
    6/26/2026Buy
    TD Cowen
    12/10/2025$40.00Perform → Outperform
    Oppenheimer
    10/10/2025Outperform → Perform
    Oppenheimer
    8/25/2025$35.00Outperform → Strong Buy
    Raymond James
    6/24/2025$13.00Mkt Perform
    Bernstein
    6/11/2025$37.00Outperform
    Raymond James
    6/2/2025$34.00Outperform
    Oppenheimer
    5/29/2025$46.00Outperform
    Evercore ISI
    More analyst ratings

    $DYN
    SEC Filings

    View All

    SEC Form 424B5 filed by Dyne Therapeutics Inc.

    424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

    7/22/26 5:21:07 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Dyne Therapeutics Inc.

    8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)

    7/22/26 5:19:38 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Dyne Therapeutics Inc.

    424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

    7/21/26 5:22:10 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rhodes Jason P sold $17,858,492 worth of shares (777,451 units at $22.97) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    7/8/26 5:35:11 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rhodes Jason P sold $10,712,550 worth of shares (504,695 units at $21.23) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    6/30/26 7:05:14 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Lucera Erick sold $48,114 worth of shares (2,362 units at $20.37), decreasing direct ownership by 2% to 121,563 units (SEC Form 4) to satisfy tax liability

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    6/26/26 4:15:07 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Dyne Therapeutics

    TD Cowen initiated coverage of Dyne Therapeutics with a rating of Buy

    6/26/26 9:18:43 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Dyne Therapeutics from Perform to Outperform and set a new price target of $40.00

    12/10/25 8:10:44 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics downgraded by Oppenheimer

    Oppenheimer downgraded Dyne Therapeutics from Outperform to Perform

    10/10/25 8:28:51 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $33,880 worth of shares (2,000 units at $16.94), increasing direct ownership by 9% to 24,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    6/9/26 5:06:18 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Posner Brian S bought $43,700 worth of shares (2,500 units at $17.48), increasing direct ownership by 12% to 22,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    6/5/26 4:10:04 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Posner Brian S bought $36,420 worth of shares (2,000 units at $18.21), increasing direct ownership by 11% to 20,000 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    5/28/26 4:11:20 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

    WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.50 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $375,150,000. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 23, 2026, subject to customary closing

    7/21/26 10:46:14 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Announces Proposed Public Offering of Common Stock

    WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne. Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also acting a

    7/21/26 4:46:51 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

    - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen once every 4 weeks resulted in a robust and statistically significant increase in dystrophin production with functional improvement observed across multiple clinical endpoints and a favorable safety profile1 - WALTHAM, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today

    7/20/26 7:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Leadership Updates

    Live Leadership Updates

    View All

    Dyne Therapeutics Appoints Barry Greene to Board of Directors

    WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more than three decades of biopharmaceutical industry experience and a track record of building and scaling innovative companies from development through commercialization across rare diseases, neuroscience, and oncology. "Dyne is approaching a planned transformation into a commercial biotechnology company. In anticipation of potential product launches and revenue generation, w

    6/22/26 4:10:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

    BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for

    2/2/26 8:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

    WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics. "We are pleased to welcome Vikram to our Board as we advance toward commercialization," said Jason

    12/23/25 7:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 5:46:12 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 4:32:40 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 4:23:11 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Financials

    Live finance-specific insights

    View All

    Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

    - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previously observed at the registrational dose - - Functional improvement was observed across multiple clinical endpoints at 6 months in REC; lung function was preserved at 6 months - - New positive long-term results from DELIVER trial showed sustained functional improvement across all assessed endpoints through 24 months - - Continued favorable safety and tolerability profile - - Submission for U.S. Accelerated Approval on track for Q2 2026 - - Investor even

    12/8/25 6:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

    WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and WebcastThe webcast will be available on the Events & Presentations page of the Investors & Medi

    12/7/25 11:00:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

    - Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically

    6/17/25 7:00:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care